Alpha Recommendation: BUY Amaero International Ltd (3DA)
You are unauthorized to view this page. Username Password Remember Me Forgot Password
Alpha Recommendation: Buy Short NASDAQ ETF (SNAS)
You are unauthorized to view this page.
Alpha Recommendation: BUY PWR Holdings (PWH)
You are unauthorized to view this page.
Alpha Recommendation: BUY Megaport (MP1)
You are unauthorized to view this page.
Bulls vs. Bears: Episode 31: Earnings Lay Bare the Hits and Misses
This week, mega-cap earnings disappoint as investors ask “where’s the revenue”, US economy starts to show cracks and middle east conflict flares up (again)
Balanced Portfolio Recommendation: BUY 7.5% Telix Pharma
You are unauthorized to view this page.
Pre-Market Pulse 16th August – “what recession?” Retail sales show US consumer still spending
Stocks closed higher for the sixth straight session Thursday, as fears of an economic slowdown were dispelled following stronger-than-expected labor market and retail sales data.
Balanced Portfolio Recommendation: Sell (stop-loss) Nufarm (NUF)
We recommend reallocating 2% of our portfolio from Elders (ELD) to Nufarm (GNC). This decision is based on the realization of a 9.2% profit in Elders and the assessment that Nufarm is currently undervalued, as supported by its recent earnings report and market conditions.
Pre-Market Pulse 15th August – Stocks drift higher as Investors put Inflation in the rear-view mirror
Stocks drifted higher driven by encouraging data showing a continued slowdown in inflation. This has raised expectations that the Federal Reserve might soon begin cutting interest rates, potentially as early as next month.
Pre-Market Pulse 14th August – Stocks rally as inflation shows further signs of easing
Stocks surged overnight as fresh evidence of easing inflation bolstered expectations for a Federal Reserve rate cut as early as next month, causing Treasury yields to drop.
Balanced Portfolio: Results from CGF (FY2024)
Overall, Challenger’s financial results for FY2024 appear to have exceeded market expectations, particularly in terms of profitability and EPS growth, despite slightly lower total Life sales. The company’s performance has been recognized by an increased dividend and a positive outlook from most analysts.